Xencor | XNCR - Assets


Xencor reported $736.85M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Xencor USD 736.85M 138.65M Mar/2026